COCP Cocrystal Pharma Inc.

1.32
+0.1  (+8%)
Previous Close 1.22
Open 1.21
Price To Book 0.58
Market Cap 41,739,253
Shares 31,620,646
Volume 75,591
Short Ratio
Av. Daily Volume 10,573
Stock charts supplied by TradingView

NewsSee all news

  1. Cocrystal Pharma Presents Data at the 26th International Symposium on Hepatitis C Virus and Related Viruses

    - Novel class of HCV antivirals targeting the NS3 helicase that can be studied for the treatment of chronic HCV infection developed utilizing Company's unique structure-based drug design platform technology - BOTHELL,

  2. Cocrystal Pharma Announces Abstract Accepted for Poster Presentation at 26th International Symposium on Hepatitis C Virus and Related Viruses

    BOTHELL, WA, Oct. 01, 2019 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ:COCP), ("Cocrystal" or the "Company"), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, today

  3. Cocrystal Pharma to Present at the 2019 Cantor Global Healthcare Conference

    - Presentation on Friday, October 4th at 1:45 PM ET - BOTHELL, WA, Sept. 26, 2019 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ:COCP), ("Cocrystal" or the "Company"), a clinical stage biotechnology company

  4. Cocrystal Pharma Presents Positive Preclinical Data for CC-42344 at the Options X for the Control of Influenza Conference

    - CC-42344 showed broad spectrum activity, excellent anti-influenza activity (EC50 <1 nM), and a strong synergistic effect with approved influenza antivirals - - Preclinical study demonstrated favorable

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2a initial data released January 22, 2019. 66% (SVR12). Full data to be presented in 2019.
CC-31244
Hepatitis C
Phase 1 trial to be initiated in 4Q 2019.
CC-42344
Influenza
Phase 2a commencement of enrolment in Hong Kong trial announced May 20, 2019. Interim data 4Q 2019.
CC-31244
Hepatitis C

Latest News

  1. Cocrystal Pharma Presents Data at the 26th International Symposium on Hepatitis C Virus and Related Viruses

    - Novel class of HCV antivirals targeting the NS3 helicase that can be studied for the treatment of chronic HCV infection developed utilizing Company's unique structure-based drug design platform technology - BOTHELL,

  2. Cocrystal Pharma Announces Abstract Accepted for Poster Presentation at 26th International Symposium on Hepatitis C Virus and Related Viruses

    BOTHELL, WA, Oct. 01, 2019 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ:COCP), ("Cocrystal" or the "Company"), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, today

  3. Cocrystal Pharma to Present at the 2019 Cantor Global Healthcare Conference

    - Presentation on Friday, October 4th at 1:45 PM ET - BOTHELL, WA, Sept. 26, 2019 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ:COCP), ("Cocrystal" or the "Company"), a clinical stage biotechnology company

  4. Cocrystal Pharma Presents Positive Preclinical Data for CC-42344 at the Options X for the Control of Influenza Conference

    - CC-42344 showed broad spectrum activity, excellent anti-influenza activity (EC50 <1 nM), and a strong synergistic effect with approved influenza antivirals - - Preclinical study demonstrated favorable